NCT00516048 - An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

Trial Locations (13)

Research Site, Keswick

Research Site, Calgary

Research Site, Vancouver

Research Site, London

Research Site, Budapest

Research Site, Gyula

Research Site, Zalaegerszeg

Research Site, Milan

Research Site, Perugia

Research Site, Rome

Research Site, Seonnam City

Research Site, Seoul

Research Site, Suwon